2018/2 GaBI Journal Table of Contents

Contents

Editor’s Letter

What to look forward to in GaBI Journal, 2018, Issue 2

Commentary

Potential changes to the FDA approach to biosimilars have a global impact

Original Research

Patient-reported outcome measures in phase III trials of LY2963016 insulin glargine and reference insulin glargine products: ELEMENT 1 and ELEMENT 2

Review Article

Protein heterogeneity and the immunogenicity of biotherapeutics

Perspective

How to realize the potential of off-patent biologicals and biosimilars in Europe? Guidance to policymakers

Regulatory

Regulation of copy biologicals in China

Biosimilar regulation and approval in Jordan

Meeting Report

Quality assessment of biosimilars in Colombia – reducing knowledge gaps

Opinion

Rationalizing FDA guidance on biosimilars—expediting approvals and acceptance

Abstracted Scientific Content

A call for coherence in EU legislation to promote generics

Source URL: https://gabi-journal.net/2018-2-gabi-journal-table-of-contents.html


Generics and Biosimilars Initiative (GaBI)
Tel: +32 474989572 | Fax: +32 14 583 048